Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis
- PMID: 33741640
- DOI: 10.1136/gutjnl-2020-323663
Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis
Abstract
Objective: The benefit of direct-acting antivirals (DAAs) against HCV following successful treatment of hepatocellular carcinoma (HCC) remains controversial. This meta-analysis of individual patient data assessed HCC recurrence risk following DAA administration.
Design: We pooled the data of 977 consecutive patients from 21 studies of HCV-related cirrhosis and HCC, who achieved complete radiological response after surgical/locoregional treatments and received DAAs (DAA group). Recurrence or death risk was expressed as HCC recurrence or death per 100 person-years (100PY). Propensity score-matched patients from the ITA.LI.CA. cohort (n=328) served as DAA-unexposed controls (no-DAA group). Risk factors for HCC recurrence were identified using random-effects Poisson.
Results: Recurrence rate and death risk per 100PY in DAA-treated patients were 20 (95% CI 13.9 to 29.8, I2=74.6%) and 5.7 (2.5 to 15.3, I2=54.3), respectively. Predictive factors for recurrence were alpha-fetoprotein logarithm (relative risk (RR)=1.11, 95% CI 1.03 to 1.19; p=0.01, per 1 log of ng/mL), HCC recurrence history pre-DAA initiation (RR=1.11, 95% CI 1.07 to 1.16; p<0.001), performance status (2 vs 0, RR=4.35, 95% CI 1.54 to 11.11; 2 vs 1, RR=3.7, 95% CI 1.3 to 11.11; p=0.01) and tumour burden pre-HCC treatment (multifocal vs solitary nodule, RR=1.75, 95% CI 1.25 to 2.43; p<0.001). No significant difference was observed in RR between the DAA-exposed and DAA-unexposed groups in propensity score-matched patients (RR=0.64, 95% CI 0.37 to 1.1; p=0.1).
Conclusion: Effects of DAA exposure on HCC recurrence risk remain inconclusive. Active clinical and radiological follow-up of patients with HCC after HCV eradication with DAA is justified.
Keywords: antiviral therapy; hepatocellular carcinoma; meta-analysis.
© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.
Conflict of interest statement
Competing interests: VS: travel funding from Bayer. FT: DSMB fees from Basilea Pharmaceutica International and ROVI; educational fees from Janssen and Ferrer. PN: consults for AbbVie, AstraZeneca, Bayer, BMS, Eisai, Gilead, Ipsen, Roche. He received grants from AbbVie and BMS. ZM: speaker fees and consultancy for Gilead and AbbVie. RT: personal fees from Merk Sharp & Dorme, Giliad Sciences and AbbVie GK. TM: personal fees from Merk Sharp & Dorme, Giliad Sciences and AbbVie GK. XF: consultancy fees for AbbVie and Gilead Sciences. HT: speaker fees from AbbVie, Gildead, MSD and Bayer. SB: consultancy fees and educational grants from: Gilead Sciences, MSD, Intercept. ED: advisory board from AbbVie; speaking and teaching from Gilead, MSD, AbbVie. M-LY: research grant from Abbott, BMS, Gilead and Merck; consultant of AbbVie, Abbott, BMS, Gilead, Merck and Roche; speaker of AbbVie, Abbott, BMS, Gilead and Merck. YA: donation-funded department funded by Toray Industries Inc., Gilead Sciences, AbbVie GK and Fuji Rebio Inc. AS: has received research funding from AbbVie and Gilead. He has served as a consultant for Wako Diagnostics, Glycotest, Exact Sciences, Roche, GRAIL, Genentech, Bayer, Eisai, Exelixis, AstraZeneca, BMS and TARGET Pharmasolutions. MK: lecture fees from Abott and AstraZeneca. J-FD: advisory committees: AbbVie, Bayer, Bristol-Myers Squibb, Falk, Genfit, Genkyotex, Gilead Sciences, HepaRegenix, Intercept, Lilly, Merck, Novartis. Speaking and teaching: Bayer, Bristol-Myers Squibb, Intercept, Genfit, Gilead Sciences, Novartis, Roche. NM: research founding, lecture fees, advisory committees and travel grants from MSD. Lecture fees, advisory committees and travel grants from AbbVie and Gilead. SP: consulting and lecturing fees from Janssen, Gilead, MSD, AbbVie, Biotest, Shinogui, Viiv and grants from Bristol-Myers Squibb, Gilead, Roche and MSD, without relation to this manuscript. JC: grants and research support from Gilead Sciences, AbbVie, MSD, Shionogi and Intercept Pharmaceuticals (all outside the submitted work). Is a speaker for Gilead Sciences and AbbVie. JLC: reports grant support and/or consultancy and lecture fees from AbbVie, Gilead Sciences, Bristol-Myers Squibb, Janssen and MSD. RV: research grant from AbbVie. GS: consultancy fees and lecture fees from Gilead and AbbVie. FPR: lecture fees AbbVie, Gilead, MSD, Biotest; travel funds AbbVie, Biotest, Kedrion; research funds AbbVie, Gilead, MSD. RB: research grants from MSD, AbbVie and Gilead. JR: educational grants from Amgen, Grüenenthal Pharma, Boehringer Ingelheim España, Janssen-Cilag, Ferrer International, Lilly, Merck Sharp & Dohme and Roche Farma. FT: consultancy fees from AstraZeneca, Bayer, BMS, Eisai and Sirtex. Lecture fees from AlfaSigma and Bayer. Research grants from Bayer. CC: consultancy fees from Bayer, EISAI, MSD, Gilead, ABV. JB: consultancy fees from Arqule, Bayer, Novartis, BMS, BTG-Biocompatibles, Eisai, Kowa, Terumo, Gilead, Bio-Alliance/Onxeo, Roche, AbbVie, Merck, Sirtex, Ipsen, Astra-Medimmune, Incyte, Quirem, Adaptimmune, Lilly, Basilea, Nerviano. Research grants from Bayer and BTG. Educational grants from Bayer and BTG. Lecture fees from Bayer, BTG-Biocompatibles, Eisai, Terumo, Sirtex, Ipsen. GC: consultancy fees from Bayer, Ipsen. MR: consultancy fees from Bayer, BMS, Roche, Ipsen, AstraZeneca and Lilly. Lecture fees from Bayer, BMS, Gilead, Lilly and Roche. Research grants from Bayer and Ipsen.
Comment in
-
End of the story: direct-acting antiviral agents are not associated with recurrence of hepatocellular carcinoma.Gut. 2022 Mar;71(3):454-456. doi: 10.1136/gutjnl-2021-324288. Epub 2021 Mar 30. Gut. 2022. PMID: 33785552 No abstract available.
Similar articles
-
Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients.J Hepatol. 2019 Aug;71(2):265-273. doi: 10.1016/j.jhep.2019.03.027. Epub 2019 Apr 6. J Hepatol. 2019. PMID: 30959157
-
Direct-acting antivirals do not increase the risk of hepatocellular carcinoma recurrence after local-regional therapy or liver transplant waitlist dropout.Hepatology. 2018 Aug;68(2):449-461. doi: 10.1002/hep.29855. Epub 2018 May 16. Hepatology. 2018. PMID: 29476694 Free PMC article.
-
Factors Associated With Increased Risk of De Novo or Recurrent Hepatocellular Carcinoma in Patients With Cirrhosis Treated With Direct-Acting Antivirals for HCV Infection.Clin Gastroenterol Hepatol. 2019 May;17(6):1183-1191.e7. doi: 10.1016/j.cgh.2018.10.038. Epub 2018 Oct 26. Clin Gastroenterol Hepatol. 2019. PMID: 30613002
-
Systematic review with meta-analysis: recurrence of hepatocellular carcinoma following direct-acting antiviral therapy.Aliment Pharmacol Ther. 2018 Jul;48(2):127-137. doi: 10.1111/apt.14823. Epub 2018 May 30. Aliment Pharmacol Ther. 2018. PMID: 29851093 Free PMC article.
-
Direct-acting antivirals and hepatocellular carcinoma in chronic hepatitis C: A few lights and many shadows.World J Gastroenterol. 2018 Jun 28;24(24):2582-2595. doi: 10.3748/wjg.v24.i24.2582. World J Gastroenterol. 2018. PMID: 29962815 Free PMC article. Review.
Cited by
-
Itemization difference of patient-reported outcome in patients with chronic liver disease.PLoS One. 2022 Feb 22;17(2):e0264348. doi: 10.1371/journal.pone.0264348. eCollection 2022. PLoS One. 2022. PMID: 35192675 Free PMC article.
-
Meta-analysis: risk of hepatitis C virus infection associated with hospital-based invasive procedures.Aliment Pharmacol Ther. 2022 Aug;56(4):558-569. doi: 10.1111/apt.17106. Epub 2022 Jun 27. Aliment Pharmacol Ther. 2022. PMID: 35758763 Free PMC article.
-
Unmet needs in the post-direct-acting antivirals era: The risk and molecular mechanisms of hepatocellular carcinoma after hepatitis C virus eradication.Clin Mol Hepatol. 2024 Jul;30(3):326-344. doi: 10.3350/cmh.2024.0155. Epub 2024 Apr 26. Clin Mol Hepatol. 2024. PMID: 38665034 Free PMC article. Review.
-
Hepatocellular carcinoma, hepatitis C virus infection and miRNA involvement: Perspectives for new therapeutic approaches.World J Gastroenterol. 2022 Jun 14;28(22):2417-2428. doi: 10.3748/wjg.v28.i22.2417. World J Gastroenterol. 2022. PMID: 35979260 Free PMC article. Review.
-
Adjuvant therapy following curative treatments for hepatocellular carcinoma: current dilemmas and prospects.Front Oncol. 2023 Apr 17;13:1098958. doi: 10.3389/fonc.2023.1098958. eCollection 2023. Front Oncol. 2023. PMID: 37139151 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical